The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
Top Cited Papers
Open Access
- 1 April 2012
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 20 (4), 749-758
- https://doi.org/10.1038/mt.2011.276
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsCancer Treatment Reviews, 2011
- Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa™)Antiviral Research, 2011
- Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entryProceedings of the National Academy of Sciences of the United States of America, 2009
- The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivationMolecular Genetics and Genomics, 2009
- Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virusGene Therapy, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia VirusPLoS Medicine, 2007
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963JCI Insight, 2007
- Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSFMolecular Therapy, 2006
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005